Structure-based Drug Design for GPCRs
By Jana Broecker, Mathieu Rappas, Robert Cooke | Oct 8, 2019
Jana Broecker, Senior Scientist, Protein Expression and Biochemist at Sosei Heptares, recently presented at an EMBO Workshop session named “Tools for Structural Biology of Membrane Proteins” in Hamburg, Germany on 7 - 9 October 2019. The presentation titled “Structure-based Drug Design for GPCRs”, co-authored by Sosei Heptares colleagues Mathieu Rappas and Robert Cooke, highlights the strong potential of GPCRs as a drug target and how Sosei Heptares’ proprietary StaR® technology has been revolutionary to GPCR drug discovery.
Tools for Structural Biology of Membrane Proteins
7 - 9 Oct 2019
European Molecular Biology Laboratory (EMBL)
GPCRs are the largest family of eukaryotic membrane proteins and are targets for many commonly used drugs. Due to their flexibility and instability outside of their native membrane, GPCRs are notoriously challenging targets for drug discovery. At Sosei Heptares these challenges have been overcome through the power of protein engineering (StaR® technology). In contrast to their wild-type counterparts, StaR® proteins are amenable for biophysical studies, fragment screening, virtual screening, and structure determination. Polymer-bounded lipid discs have proven very useful in GPCR research, particularly with early StaRs.